Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
							Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)


Facebook
        Twitter
        LinkedIn
        Syndicate





Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) of Pneumococcal Vaccines for Immunocompromised Children Aged 6 through 18 Years																									Related Pages
												On This Page
			MethodsTablesReferences
		
Printer friendly version of this page Cdc-pdf[9 pages]
Methods
GRADE was used to evaluate 13-valent Pneumococcal Conjugate Vaccine (PCV13) for routine use among immunocompromised children aged 6 through 18 years.
Evidence of benefits, harms, values and preferences, and cost-effectiveness were reviewed in accordance with GRADE methods.[1] The primary policy question was “Should PCV13 be administered routinely to children aged 6 through 18 years with immunocompromising conditions?” Due to the limited body of evidence on vaccine efficacy and safety among persons with most immunocompromising conditions and varying formulations of pneumococcal conjugate vaccines (PCV), 7-,9-, and 13-valent PCVs were evaluated using data for HIV-infected adults and children, and children with sickle cell disease. Studies with PCV7 and PCV9 were used as a proxy when no PCV13 studies were available; PCV7 and PCV9 have the same formulation as PCV13 with 7 antigens in common. The benefits considered in GRADE included critical outcomes of prevention of invasive pneumococcal disease (IPD), pneumococcal pneumonia, death, and hospitalizations due to pneumococcal disease; vaccine-induced immunogenicity was considered an important outcome. The harms considered were serious adverse events and systemic adverse events. Evidence type for each critical or important outcome was derived through a review of study design, risk of bias, inconsistency, indirectness, and imprecision.
Evidence used to evaluate efficacy of PCV13 to prevent IPD was from two randomized controlled trials (RCT): PCV9 among HIV-infected children in South Africa.[2] and of PCV7 among HIV-infected adults in Malawi.[3] The effectiveness of PCV13 against IPD was assumed to be the same as that estimated from a pre/post observational study of PCV7 in children <10 years with sickle cell disease (SCD).[4] Evidence used to evaluate efficacy of PCV13 to prevent critical outcomes of pneumonia and death was from the same RCT in South Africa among HIV-infected children.[2] Evidence was not available for critical outcome of hospitalizations. There are two studies on immunogenicity for children with SCD: an unpublished pre/post study of immunogenicity of PCV13 in children aged 6 through 18,[5] and a published immunogenicity study of PCV7 and PPSV compared to PPSV alone.[6] There are three published studies for HIV-infected children: one pre/post study and two clinical trials for immunogenicity of PCV.[7-9] Four RCTs of PCV7 have been conducted in HIV-infected adults.[10-13] Safety of PCV13 was evaluated based on a pre/post study in children with SCD[5] and three RCTs of PCV7 in HIV-infected adults.[10-12]
Tables
Table 1. Benefits: 13-valent Pneumococcal Conjugate Vaccine in immunocompromised older children
Benefits: 13-valent Pneumococcal Conjugate Vaccine in immunocompromised older children
Outcome
No. subjects
(# studies)
Incidence in unvaccinated (cases/100,000)
Incidence in vaccinated (cases/100,000)
Vaccine efficacy (95% CI)
Absolute risk per 100,000
Number needed to vaccinateInvasive Pneumococcal Disease
RCTs in HIV-infected individuals39,836
(1 RCT of PCV9, HIV+ children, South Africa)[2]
131
45
65%
(24, 86)a
N/A
N/A496
(1 RCT of PCV7, HIV+ adults, Malawi)[3]
7,661
2,016
74%
(30, 90)b
N/A
N/A197c
61d
69%
(44, 83)e
135d
736dRetrospective cohort study in children <10 years with sickle cell disease[4]1,247
1.7
0.5
81% (19, 96)f
N/A
N/ADeath
39,836
(1 RCT of PCV9, HIV+ children, South Africa)[2]
884
833
6% (P-value=0.63)a
N/A
N/APneumonia
39,836
(1 RCT of PCV9, HIV+ children, South Africa)[2]
1,049
914
13% (-7, 29)a
N/A
N/AImmunogenicity- Antibody response to vaccine serotypesOutcome
Study design
Number in study
ResultsGMFR
PCV13 in children with SCDPre/Post[5]
158
A single dose of PCV13 was immunogenic in SCD patients; none to modest increases in titers post-dose 2 of PCV13 administered 6 months later vs. dose 1Study design
Number in PCV arm
Number in PPSV23 arm
ResultsPCV7 in children with SCDGMC
RCT[6]
(2 doses of PCV7 +PPSV23 vs. PPSV23 only)
11
12
Significant increases in GMC post 1 dose PCV7, no additional benefit post dose 2 of PCV7; response as good or better for some serotypes post 1 dose PCV7 vs PPSV23PCV7 in HIV+ adults% with ≥4-fold increase in GMT
RCT[10]
(2 doses of PCV7 vs. PPSV23)
15
16
GMTs higher for PCV7 vs. PPSV23 (significance not assessed post 1st doe osf PCV7); % with ≥4-fold increase in GMT higher for PCV7 vs. PPSV23 for 4/5 serotypes (significant for 1/4 serotypes)% with ≥2-fold rise in IgG levels and >1μg/ml
RCT[11]
106
106
No significant difference in outcome between PCV7 and PPSV23 (OR: 1.36, 95%CI 0.82-2.25)RCT[12]
102
100
No significant difference in outcome between PCV7 and PPSV23RCT[13]
131
73
Greater response for PCV7 vs. PPSV23 (57% vs. 36%, respectively; OR: 2.6 [95% CI, 1.4-5.0])Study design
Number in PCV group
Number in placebo group
ResultsPCV7 in HIV+ childrenGMC
Pre/post[7]
225
N/A
76–96% achieved >0.5 μg/mL after 1 dose and 62-88% achieved >1.0 μg/mL after 2 doses of PCV7 for five serotypes testedRCT[8]
30
36
Proportion >0.35 μg/mL: 63-93% (1 month after 3rd dose of PCV9)a;
Proportion ≥0.2 μg/mL and ≥0.35 μg/mL (5.3 years after 3rd dose of PCV9):
39-100% achieved ≥0.2 g/mL and
19-81% achieved ≥0.35 μg/mL
for each of seven serotypes testedRCT[9]
30
15
>95% achieved 0.15 μg/mL and 80% achieved 0.5 μg/mL after 3rd PCV7 dose; 88-100% achieved a 4-fold rise after 3rd PCV7 dose for each of seven serotypes testedTable 1 Footnotes
aVaccine efficacy for a 3-dose primary series of PCV9 administered at 6, 10, and 14 weeks of agebVaccine efficacy for 2 doses of PCV7 administered 4 weeks apart estimated using hazard ratioscIncidence of PCV13 type IPD among children aged 6-18 years with HIV/AIDS in the US, Active Bacterial Core surveillance (ABCs), CDC unpublished 2007-09, ABCs incidence data was only used to compute the number needed to vaccinate and not used in the evidence profiledIncidence in vaccinated, absolute risk, and number needed to vaccinate was estimated using VE estimate from two RCTs[2],[3] and applying it to baseline incidence of PCV13 type IPD in the US population with HIV/AIDSeSummary vaccine efficacy estimated using data from two RCTs[2],[3]fVaccine effectiveness for ≥1 doses of PCV7 adjusted for herd effects
Abbreviations:
GMC= Geometric Mean Concentration
GMT= Geometric Mean Titers
IgG= Immunoglobulin G
OR= Odds Ratio
GMFR=Geometric Mean Fold Rise
N/A= Not applicable
RCT= Randomized Controlled Trial
**Top of Page
Table 2. Harms: 13-valent Pneumococcal Conjugate Vaccine in immunocompromised children
Harms: 13-valent Pneumococcal Conjugate Vaccine in immunocompromised children
Outcome
Study design
Incidence in controls
Incidence in vaccinated
CommentsSerious adverse events (SAE)Overall SAE
1 Pre/Post,[5]
3 RCTs[10-12]
N/A
0
No serious adverse events reportedDeaths
1 Pre/Post,[5]
3 RCTs[10-12]
N/A
0
No deathsSystemic Adverse EventsStudy design
Proportion reportingFatigue
Pre/post study, 2 doses, children with SCD[5]
66.1%Headache
Pre/post study, 2 doses, children with SCD[5]
53.6%New generalized muscle pain
Pre/post study, 2 doses, children with SCD[5]
74.8%Vomiting
Pre/post study, 2 doses, children with SCD[5]
15.4%Diarrhea
Pre/post study, 2 doses, children with SCD[5]
15.4%New generalized joint pain
Pre/post study, 2 doses, children with SCD[5]
39.8%Study design
Incidence in controls
Incidence in vaccinated
CommentsMild, self-limited secondary reactions
1 RCT[12]
20%
34%
P=0.072 RCTs[10],[11]
N/A
N/A
No serious adverse events; no differences in systemic adverse events reportedTable 2 Footnotes
N/A= not applicable
RCT= Randomized Controlled Trial
**Top of Page
Table 3. Evidence Type for Benefits and Harms: 13-valent Pneumococcal Conjugate Vaccine in immunocompromised older children
Evidence Type for Benefits and Harms: 13-valent Pneumococcal Conjugate Vaccine in immunocompromised older children
Outcome
Study design (# studies)
Risk of bias
Inconsistency
Indirectness
Imprecision
Evidence typeaBenefitsInvasive Pneumococcal Disease
RCT (2)
No serious
No serious
Very seriousb
No serious
3Observational (1)
No serious
N/A
No serious
No serious
3Pneumonia
RCT (1)
No serious
N/A
Very seriousb
No serious
3Death
RCT (1)
No serious
N/A
Very seriousb
No serious
3Antibody response to vaccine types
Pre/post (2)
No serious
No serious
No serious
No serious
3RCT (4) adults, RCT (2) children
No serious
No serious
Very seriousc
No serious
3HarmsSystemic adverse events
Pre/post (1)
No serious
N/A
No serious
No serious
3RCT (5)
No serious
No serious
Very seriousc
No serious
3Table 3 Footnotes
N/A= Not applicable
a Evidence type:
1= Randomized controlled trials (RCTs), or overwhelming evidence from observational studies.
2= RCTs with important limitations, or exceptionally strong evidence from observational studies.
3= Observational studies, or RCTs with notable limitations.
4= Clinical experience and observations, observational studies with important limitations, or RCTs with several major limitations.
b Indirectness due to 1) different intervention (PCV9, 3 doses; PCV7, 2 doses) and 2) different population (South Africa, infants; Malawi, adults)c Indirectness due to 1) different intervention (PCV7 or PCV9) and 2) different population (adults)
**Top of Page
Table 4. Summary of Evidence: 13-valent Pneumococcal Conjugate Vaccine in immunocompromised children
Summary of Evidence: 13-valent Pneumococcal Conjugate Vaccine in immunocompromised children
Comparison
Outcome
Study design
(# studies)
Findings
Evidence type
Overall evidence typePCV9 or PCV7 vs. No vaccination
Invasive Pneumococcal Disease
RCT (2)
Decreased risk among vaccinated
3
3PCV9 vs. No vaccination
Pneumonia
RCT (1)
Decreased risk among vaccinated
3
3PCV9 vs. No vaccination
Death
RCT (1)
No change in outcome
3
3PCV13, PCV7, or PCV9 vs PPSV or placebo
Antibody response to vaccine types
Pre/post (2)
RCT (6)
Increases in antibody titers post-vaccination
3
3PCV13 vs. PCV7
SAEb
Pre/Post (1)
RCT (5)
No serious adverse events
3
3Table 4 Footnotes
a Overall evidence type is based on the weakest evidence type among the critical outcomes. Evidence was not available and, evidence type could not be assessed for critical outcomes of death, hospitalizations due to pneumococcal diseaseb SAE= Serious Adverse Events
**Top of Page
Table 5. Considerations for Formulating Recommendations: 13-valent Pneumococcal Conjugate Vaccine in immunocompromised children
Considerations for Formulating Recommendations: 13-valent Pneumococcal Conjugate Vaccine in immunocompromised children
Key factors
CommentsEvidence type for benefits and harms
Indirectness & lack of evidence for 3 of 4 critical disease outcomesBalance between benefits and harms
Benefits outweigh harms
Very high burden of disease in immunocompromised childrenValue
ACIP pneumococcal work group consensus regarding the importance of preventing critical pneumococcal outcomesCost-effectiveness
Uncertainty regarding costs/benefits relative to PPSV23Summary: Benefits are greater than potential harms. High values were placed on prevention of the morbidity and mortality of pneumococcal infection among immunocompromised children. (*recommendation category A; evidence type 3)*
The ACIP Pneumococcal Work Group concluded that broader serotype protection can be achieved through use of both PCV13 and PPSV23 among immunocompomised children 6 through 18 years old; 49% of IPD in this group is caused by PCV13 serotypes, and an additional 23% by serotypes in PPSV23 not included in PCV13. Evidence from immunogenicity studies demonstrate that antibody response is non-inferior or superior when PCV is given before PPSV23 compared to PPSV23 administration before PCV.[11,12,14] Although the optimal interval for PCV13 followed by PPSV23 has not been specifically studied, significant increases in antibody as well as non-inferior to superior response compared to PPSV23 alone has been observed when PPSV23 was given eight weeks after PCV7.[14] For children previously immunized with PPSV23, waiting at least 8 weeks after PPSV23 before giving a dose of PCV13 may provide a better immune response (expert opinion).
The Work Group concluded that Category A (desirable consequences clearly outweigh undesirable consequences) recommendation for the use of PCV13 (evidence type 3) among PCV13-naïve immunocompromised children is warranted because 1) there remains an extremely high burden of pneumococcal disease among immuocompromised children, and 2) indirect effects of PCV13 use in young children are unlikely to eliminate disease caused by PCV13 serotypes in older children with immunocompromising conditions.
**Top of Page
References
Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). *Vaccine.* 2011;29(49):9171-9176.
Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. *New England Journal of Medicine.* Oct 2 2003;349(14):1341-1348.
French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. *The New England journal of medicine.* Mar 4 2010;362(9):812-822.
Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. *Pediatrics.* Mar 2008;121(3):562-569.
Montalembert M, Abboud MR, Fiquet A, et al. A 2-dose schedule of 13-valent pneumococcal conjugate vaccine (PCV13) given to children with sickle cell disease previously immunized with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study. *54th Annual Meeting of the American Society of Hematology, Atlanta, GA, USA.* December 8-11, 2012.
Vernacchio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. *J Pediatr.* 1998;133(2):275-278.
Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. *The Pediatric infectious disease journal.* Oct 2006;25(10):920-929.
Madhi SA, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. *The Pediatric infectious disease journal.* May 2005;24(5):410-416.
Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. *Pediatrics.* Jul 2003;112(1 Pt 1):66-73.
Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. *Vaccine.* Nov 12 2002;20(3-4):545-553.
Lesprit P, Pedrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. *Aids.* Nov 30 2007;21(18):2425-2434.
Penaranda Ma, Payeras Ab, Cambra Ac, Mila Jc, Riera Ma, the Majorcan Pneumococcal Study G. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. *Aids.* 2010;24(8):1226-1228.
Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. *J Infect Dis.* Oct 1 2010;202(7):1114-1125.
Feikin DR, Elie CM, Goetz MB, et al. Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults. *Clin Diagn Lab Immunol.* Jan 2004;11(1):137-141.**Top of Page

			View Page In:Cdc-pdf PDF [206K]
							
								Page last reviewed:  April 15, 2016						Content source:  	National Center for Immunization and Respiratory Diseases homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov





Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue